Skip to main content
David Young, MD, Oncology, Rancho Mirage, CA

DavidEugeneYoungMD

Oncology • Rancho Mirage, CA

Physician

Join to view full profile

Dr. Young is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Young's full profile

Already have an account?

  • Office

    34490 Bob Hope Dr
    Rancho Mirage, CA 92270
    Phone+1 760-568-3613
    Fax+1 760-340-5189

Education & Training

  • University of California Davis Health
    University of California Davis HealthFellowship, Hematology and Medical Oncology, 1988 - 1989
  • Los Angeles County-Harbor-UCLA Medical Center 1
    Los Angeles County-Harbor-UCLA Medical Center 1Fellowship, Hematology and Medical Oncology, 1986 - 1988
  • San Joaquin General Hospital
    San Joaquin General HospitalResidency, Internal Medicine, 1980 - 1983
  • San Joaquin General Hospital
    San Joaquin General HospitalInternship, Transitional Year, 1979 - 1980
  • University of Illinois College of Medicine
    University of Illinois College of MedicineClass of 1979

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1980 - 2026
  • AR State Medical License
    AR State Medical License 1999 - 2001
  • TN State Medical License
    TN State Medical License 1998 - 2001
  • CO State Medical License
    CO State Medical License 1983 - 1987
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2014

Clinical Trials

Publications & Presentations

Abstracts/Posters

  • Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
    David E. Young, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • PROCESSA PHARMACEUTICALS : ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117 (Form 8-K)
    PROCESSA PHARMACEUTICALS : ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117 (Form 8-K)June 17th, 2021
  • Processa Pharmaceuticals Enters into a Licensing Agreement with Ocuphire Pharma, Inc., for the Development of Rx-3117
    Processa Pharmaceuticals Enters into a Licensing Agreement with Ocuphire Pharma, Inc., for the Development of Rx-3117June 17th, 2021
  • Processa Pharmaceuticals Entered into a Contingent Precedent in-Licensing Agreement with Elion Oncology for the Development of Eniluracil (pcs6422) for the Treatment of Advanced Gastrointestinal...
    Processa Pharmaceuticals Entered into a Contingent Precedent in-Licensing Agreement with Elion Oncology for the Development of Eniluracil (pcs6422) for the Treatment of Advanced Gastrointestinal...August 27th, 2020
  • Join now to see all

Dr. David Young, Dr. David Young, MD, Dr. D Young, Dr. David Eugene Young